Novartis acquires inflammasome blocker company IFM TreNovartis has aquired all outstanding capital stock and paid US$310m upfront to Boston-based IFM Tre Inc., which commercialises three inflammasome blockers designed to treat chronic inflammatory dise … more ➔
EMA recommends bluebird’s ?-thalassemia gene therapyThe European Medicines Agency has granted conditional approval for bluebird bio NV’s gene therapy Zynteglo (LentiGlobin BB305) to treat the rare disease transfusion-dependent ?-thalassemia at its … more ➔
Selvita to spin out cancer businessKrakow-based Selvita S.A. has announced it will spin out its oncology unit this year resulting in two public companies, a CRO and a cancer therapeutics developer. more ➔
123rf.com/guniita Polyneuron Pharma raise CHF22.5m in Series A financingThe CHF22.5m Series A financing round of the Swiss specialist for autoimmune diseases was led by Sofinnova Partners and New Enterprise Associates together with contributions of existing investors. more ➔
Genfit prices IPO at $135mFrench liver disorder specialist Genfit SA has announced the pricing of its Nasdaq IPO of ADS and European private placement. more ➔
Evotec partners with Mark Foundation for Cancer Research Evotec AG and The Mark Foundation for Cancer Research have inked a R&D collaboration aimed at developing novel immunooncological drugs more ➔
Hookipa Pharma files for US-$86m IPOUS-Austrian arenavirus-based cancer and infectious diseases specialist Hookipa has has filed a prospectus for an US$86M Nasdaq IPO. more ➔
New approach to treat eye cancerA research team from Germany and Mexico has successfully targeted uveal melanoma (UM), the most common type of eye cancer. more ➔
Pfizer buys stake in liver gene therapy player VivetPfizer Inc has paid €45m upfront to French gene therapy specalist Vivet Therapeutics in a licence option deal for Vivet’s preclinical Wilson disease candidate VTX-801. more ➔
Sotio on track for 2nd Phase III trialAfter positive preliminary results of Sotio’s SOV02 trial in ovarian cancer had been presented last year, the final analysis confirmed the survival benefits. The Czech biotech company now plans to initiate … more ➔
123rf.com/guniita
